It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Despite this similarity, the two companies are not similarly situated. Ten years ago CRISPR began working with Vertex as part of a strategic collaboration which morphed into an agreement to co ...

getting the CRISPR molecules into the cells they need to be in," especially for therapeutics doing their work in the body, Foss said. "Our technology solves the high unmet need in the brain." ...

It promised to use engineering principles and a new CRISPR enzyme, called CasX, to create better and safer gene editors than those of other companies. The company’s work on CasX attracted ...

"As CRISPR therapies enter the clinic, there is a growing need to ensure that these tools are as safe as possible, and this work tackles one aspect of that challenge," said Zhang, who is also a co ...

Bioengineering Professor Kiana Aran is one of three inaugural winners of the Sony Women in Technology Award with Nature. She ...

CRISPR Therapeutics AG (NASDAQ ... Furthermore, the company's ongoing work in oncology, particularly with allogeneic CAR-T cell therapies, could revolutionize cancer treatment by providing off ...

The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or embryos ... “Given the broad interest in this topic, the work will probably be discussed widely and might ultimately ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Number of Hedge Fund Holders: 30 Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a biotech company at the forefront of CRISPR-Cas9 gene-editing technology, working on innovative therapies for both in ...